Market Research Logo

Global Gastrointestinal Therapeutics Market 2016-2020

Global Gastrointestinal Therapeutics Market 2016-2020

About Gastrointestinal Disorders

Gastrointestinal disorders include both functional and motility disorders affecting the gastrointestinal tract. Functional disorders involve an abnormality in the working of the gastrointestinal tract. They are the most common type of disorders and present with disturbances in motility, visceral hypersensitivity, changes in the mucosal and immune function, variations in central nervous system processing, and altered gut microbiota. Motility disorders are characterized by changes in the movement of the gastrointestinal tract and the transfer of its contents. Some of the most common gastrointestinal functional and motility disorders include IBS, GERD, Crohn’s disease, ulcerative colitis, and peptic ulcers.

Technavio’s analysts forecast the global gastrointestinal therapeutics market to grow at a CAGR of 6.5% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global gastrointestinal therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various gastrointestinal disorders including IBD, and irritable bowel syndrome (IBS).

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Gastrointestinal Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Johnson & Johnson
  • Takeda
  • Allergan
  • UCB
Other prominent vendors
  • 4SC
  • Ajinomoto Pharmaceuticals
  • Alfa Wassermann
  • Alizyme
  • Amgen
  • Anterogen
  • Ardelyx
  • Arena Pharmaceuticals
  • Astellas
  • AstraZeneca
  • Astellas Pharma
  • Avaxia Biologics
  • Biogen Idec
  • BioLineRx
  • Celgene
  • ChemoCentryx
  • Cosmo Pharmaceuticals
  • Drais Pharmaceuticals
  • Eisai
  • Eli Lilly
  • Enlivex Therapeutics
  • F. Hoffmann-La Roche
  • Ferring Pharmaceuticals
  • FF Pharma
  • Galapagos
  • Gilead Sciences
  • GlaxoSmithKline
  • Hutchison Medi Pharma
  • Immune Pharmaceuticals
  • InDex Pharmaceuticals
  • Ironwood Pharmaceuticals
  • Kaken Pharmaceutical
  • Kang Stem Biotech
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Lexicon Pharmaceuticals
  • Lipid Therapeutics
  • Meda
  • Merck
  • Mesoblast
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Morphotek
  • Neovacs
  • Nestle
  • Norgine
  • Novartis
  • Ono Pharmaceutical
  • Pfizer
  • Procter & Gamble
  • Qu Biologics
  • Receptos
  • RedHill Biopharma
  • Salix Pharmaceuticals
  • Shield Therapeutics
  • Sterna Biologicals
  • Synergy Pharmaceuticals
  • Synthetic Biologics
  • TiGenix
  • Tillotts Pharma
  • TopiVert
  • TSD Japan
  • Zeria Pharmaceutical
Market driver
  • Tentative approval of late stage molecules
  • For a full, detailed list, view our report
Market challenge
  • Discontinuation of drugs under development and from the market
  • For a full, detailed list, view our report
Market trend
  • Emergence of biosimilars
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Gastrointestinal Therapeutics Market 2016-2020

Technavio recognizes the following companies as the key players in the global gastrointestinal therapeutics market: AbbVie, Johnson & Johnson, Takeda, Allergan, and UCB.

Other Prominent Vendors in the market are: 4SC, Ajinomoto Pharmaceuticals, Alfa Wassermann, Alizyme, Amgen, Anterogen, Ardelyx, Arena Pharmaceuticals, Astellas, AstraZeneca, Astellas Pharma, Avaxia Biologics, Biogen Idec, BioLineRx, Celgene, ChemoCentryx, Cosmo Pharmaceuticals, Drais Pharmaceuticals, Eisai, Eli Lilly, Enlivex Therapeutics, F. Hoffmann-La Roche, Ferring Pharmaceuticals, FF Pharma, Galapagos, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Kaken Pharmaceutical, Kang Stem Biotech, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, Lipid Therapeutics, Meda, Merck, Mesoblast, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Neovacs, Nestle, Norgine, Novartis, Ono Pharmaceutical, Pfizer, Procter & Gamble, Qu Biologics, Receptos, RedHill Biopharma, Salix Pharmaceuticals, Shield Therapeutics, Sterna Biologicals, Synergy Pharmaceuticals, Synthetic Biologics, TiGenix, Tillotts Pharma, TopiVert, TSD Japan, and Zeria Pharmaceutical.

Commenting on the report, an analyst from Technavio’s team said: “Patient assistance programs will be a key trend for market growth. Under this program, the vendors in the market are providing co-pay assistance to the individuals purchasing the indicated medications for gastrointestinal disorders. Such patient assistance programs will further boost the growth of the market, as the patient pool receives financial support for the otherwise costly treatment. For instance, in the US, individuals who cannot afford expensive treatments are provided financial assistance by state and federal agencies such as Medicare, Social Security, and Medicaid. People can also apply for free medications or financial co-pay assistance for the drug.”

According to the report, increasing consumption of biologics will be a key driver for market growth. Biologics, available as either intravenous or subcutaneous injections, are increasingly becoming the treatment of choice for IBD. These therapeutics act by either blocking the interleukins or the TNF-α. HUMIRA (adalimumab), Remicade (infliximab), Simponi (golimumab), and Cimzia (Certolizumab pegol) are some anti-TNF agents, and Tysabri (natalizumab) and ENTYVIO (vedolizumab) are some anti-integrin agents available in the market for the treatment of ulcerative colitis and Crohn's disease. Apart from the already approved drugs, many biologics are still under development for the treatment of IBD.

Further, the report states that the unknown etiology of IBD and IBS is a challenge to the market. Some researchers consider heredity to be an integral factor in developing IBD. Research studies indicate that a family history of IBD will increase the risk of an individual developing ulcerative colitis or Crohn's disease.



Companies Mentioned

AbbVie, Johnson & Johnson, Takeda, Allergan, UCB, 4SC, Ajinomoto Pharmaceuticals, Alfa Wassermann, Alizyme, Amgen, Anterogen, Ardelyx, Arena Pharmaceuticals, Astellas, AstraZeneca, Astellas Pharma, Avaxia Biologics, Biogen Idec, BioLineRx, Celgene, ChemoCentryx, Cosmo Pharmaceuticals, Drais Pharmaceuticals, Eisai, Eli Lilly, Enlivex Therapeutics, F. Hoffmann-La Roche, Ferring Pharmaceuticals, FF Pharma, Galapagos, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Kaken Pharmaceutical, Kang Stem Biotech, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, Lipid Therapeutics, Meda, Merck, Mesoblast, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Neovacs, Nestle, Norgine, Novartis, Ono Pharmaceutical, Pfizer, Procter & Gamble, Qu Biologics, Receptos, RedHill Biopharma, Salix Pharmaceuticals, Shield Therapeutics, Sterna Biologicals, Synergy Pharmaceuticals, Synthetic Biologics, TiGenix, Tillotts Pharma, TopiVert, TSD Japan, Zeria Pharmaceutical.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Global gastrointestinal therapeutics market: Key buying criteria 2015
      • Table Global gastrointestinal therapeutics market: Key customer segments
  • Pipeline portfolio
    • Ulcerative colitis
      • Table Global ulcerative colitis therapeutics market: Pipeline portfolio
    • Crohn's disease
      • Table Global Crohn's disease therapeutics market: Pipeline portfolio
    • IBS
      • Table Global IBS therapeutics market: Pipeline portfolio
  • Market landscape
    • Global gastrointestinal therapeutics market
      • Table Global gastrointestinal therapeutics market snapshot: Developed and emerging markets 2015
      • Table Global gastrointestinal therapeutics market: Factors affecting growth 2015 and 2020
      • Table Approval and patent expiries of top selling biologics
      • Table Global gastrointestinal therapeutics market 2016-2020 ($ billions)
      • Table Global gastrointestinal disorder therapeutics market segmentation: Growth cycle analysis
      • Table Five forces analysis
  • Market segmentation by disease type
    • Overview
      • Table Global gastrointestinal therapeutics market by disease type: Revenue share 2015
      • Table Global gastrointestinal therapeutics market by disease type: Growth lifecycle analysis
      • Table Global gastrointestinal therapeutics market by disease type 2015-2020
  • Global IBD therapeutics market
    • Table Global IBD therapeutics market by type: Revenue share 2015
    • Table Global IBD therapeutics market by type 2015-2020
    • Table Global IBD therapeutics market segmentation: Growth lifecycle analysis
    • Global ulcerative colitis drugs market
      • Table Global ulcerative colitis drugs market 2015-2020 ($ billions)
    • Global Crohn's disease drugs market
      • Table Global Crohn's disease drugs market 2015-2020 ($ billions)
    • Market segmentation by molecule type
      • Table Global IBD therapeutics market by molecule type 2015
      • Table Biologics in global IBD therapeutics market 2015-2020 ($ billions)
      • Table Small molecules in global IBD therapeutics market 2015-2020 ($ billions)
  • Global IBS therapeutics market
    • Table Global IBS therapeutics market 2015-2020 ($ billions)
  • Global gastrointestinal OTC drugs market
    • Table Drugs that underwent Rx-to-OTC switch in the US
    • Table Global gastrointestinal OTC drugs market 2015-2020 ($ billions)
  • Geographical segmentation
    • Global gastrointestinal therapeutics market by geography 2015-2020
      • Table Global gastrointestinal therapeutics market by geography 2015-2020
      • Table Global gastrointestinal therapeutics market by geography 2015 and 2020
      • Table Global gastrointestinal therapeutics market by geography 2015-2020 ($ billions)
      • Table Global gastrointestinal therapeutics market by geography: Market share 2015
      • Table Global gastrointestinal therapeutics market by geography: Disease type 2015
      • Table Global gastrointestinal therapeutics market by geography: Market growth lifecycle analysis 2015
      • Table Global gastrointestinal therapeutics market by country: Revenue and growth rate analysis
    • Gastrointestinal therapeutics market in Americas
      • Table Opportunity analysis of gastrointestinal therapeutics market in Americas
      • Table Gastrointestinal therapeutics market in Americas 2015-2020 ($ billions)
    • Gastrointestinal therapeutics market in EMEA
      • Table Opportunity analysis of gastrointestinal therapeutics market in EMEA
      • Table Gastrointestinal therapeutics market in EMEA 2015-2020 ($ billions)
    • Gastrointestinal therapeutics market in APAC
      • Table Opportunity analysis of gastrointestinal therapeutics market in APAC
      • Table Gastrointestinal therapeutics market in APAC 2015-2020 ($ billions)
  • Market drivers
    • Table Impact of drivers and challenges on global gastrointestinal therapeutics market
    • Increasing consumption of biologics
      • Table Biologics for IBD: market share 2012-2022
      • Table Few biologics under development for gastrointestinal disorders
    • Tentative approval of late stage molecules
    • Development of novel therapies using innovative technologies
    • Improved diagnostic tools increasing the treatment-seeking population
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Increased consumption of OTC medications
      • Table Rx-to-OTC switch: Promoters and inhibitors
    • Unknown etiology of IBD and IBS
    • Discontinuation of drugs under development and from the market
      • Table Gastrointestinal therapeutics discontinued from development or market
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Global gastrointestinal therapeutics market: Impact assessment of key trends
    • Patient assistance programs
      • Table Gastrointestinal therapeutics with patient assistance programs in US
    • Emergence of biosimilars
      • Table Biosimilars under development for gastrointestinal disorders
    • Rise in self-medication
    • Focus on regenerative medicines
      • Table Regenerative medicines for IBD under development
    • Strategic alliances and M&A
  • Vendor landscape
    • Competitive scenario
      • Table Key vendors ranking 2015
      • Table Key vendors: Geographical presence
      • Table Market vendors: Competitive scenario 2015-2020
    • Other prominent vendors
  • Key vendor analysis
    • AbbVie
      • Table AbbVie: Profile
      • Table AbbVie: Strength analysis
      • Table AbbVie: Growth strategy matrix
      • Table AbbVie: Opportunity assessment
      • Table AbbVie: YoY growth and revenue of HUMIRA 2012-2014 ($ billions)
    • Johnson & Johnson
      • Table Johnson & Johnson: Profile
      • Table Johnson & Johnson: Strength analysis
      • Table Johnson & Johnson: Growth strategy matrix
      • Table Johnson & Johnson: Opportunity assessment
      • Table Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
    • Takeda
      • Table Takeda: Profile
      • Table Takeda: Strength analysis
      • Table Takeda: Growth strategy matrix
      • Table Takeda: Opportunity assessment
    • Allergan
      • Table Allergan: Profile
      • Table Allergan: Strength analysis
      • Table Allergan: Growth strategy matrix
      • Table Allergan: Opportunity assessment
      • Table Allergan: Revenue of gastrointestinal therapeutics 2015 ($ millions)
    • UCB
      • Table UCB: Profile
      • Table UCB: Strength analysis
      • Table UCB: Growth strategy matrix
      • Table UCB: Opportunity assessment
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report